Full text is available at the source.
Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists
Discovery of new drugs that activate both blood sugar control and appetite regulation receptors
AI simplified
Abstract
A novel oxyntomodulin-based dual agonist, OXM-7, shows potent hypoglycemic effects in mice.
- OXM-7 demonstrated both acute and long-acting hypoglycemic effects in ICR and db/db mice.
- Twice-daily administration of OXM-7 in diet-induced obesity mice led to significant weight loss.
- OXM-7 normalized lipid metabolism and improved glucose control in obese mice.
- In mice with diet-induced nonalcoholic steatohepatitis, OXM-7 significantly reversed liver fat accumulation.
- The treatment also reduced serum and liver lipid levels, indicating potential benefits for metabolic health.
AI simplified